GLP-1 Medications for Patients Over 60: Benefits, Risks, and Clinical Considerations

GLP-1 medications are increasingly prescribed to adults over 60 — a population that stands to benefit significantly from weight-related metabolic improvements but also requires more careful clinical management. Older adults aren't just "older versions of younger patients." They have distinct physiological considerations that affect how GLP-1 therapy should be approached.

Why GLP-1 Therapy Makes Sense for Older Adults

Obesity in adults over 60 is strongly associated with:

• Type 2 diabetes and insulin resistance
• Cardiovascular disease — the leading cause of death in this age group
• Osteoarthritis and mobility limitations
• Obstructive sleep apnea
• Reduced functional independence

The SELECT trial demonstrated a 20% reduction in major cardiovascular events with semaglutide in overweight/obese adults — a finding particularly relevant for patients over 60, who carry the highest cardiovascular risk. Weight loss that improves mobility, reduces joint pain, and enhances daily function can be genuinely life-changing for older patients in ways that transcend the number on the scale.

The Sarcopenia Concern

The most significant clinical concern with GLP-1 therapy in older adults is muscle loss (sarcopenia). All weight loss — regardless of method — includes some lean mass loss, typically 25–40% of total weight lost. For younger adults, this is usually recoverable. For adults over 60, muscle mass is harder to rebuild and its loss carries real consequences:

• Fall risk increases with reduced muscle strength
• Functional independence declines
• Metabolic rate drops, increasing future weight regain risk
• Bone density may decrease alongside muscle loss

Mitigation strategies are not optional for older patients — they're core to the treatment plan:

• Resistance training 2–3 times per week (even bodyweight exercises make a measurable difference)
• Protein intake of 1.0–1.2g per kilogram of body weight daily (higher than younger adult recommendations)
• DEXA or body composition monitoring to track lean mass preservation
• Physical therapy referral for patients with mobility limitations that prevent exercise

Dosing Considerations

Older adults may benefit from more conservative titration schedules:

• Slower dose escalation: Extending time at each titration step from 4 weeks to 6–8 weeks reduces GI side effects that can cause problematic dehydration in older patients.
• Lower maintenance doses: Some older patients achieve clinically meaningful weight loss at intermediate doses and don't need maximum dosing.
• Kidney function monitoring: Age-related decline in renal function affects drug clearance. eGFR should be checked before initiation and monitored periodically.

Polypharmacy Awareness

Adults over 60 are more likely to take multiple medications — antihypertensives, statins, blood thinners, diabetes drugs, thyroid medication. GLP-1's effect on gastric emptying can alter the absorption of oral medications. A comprehensive medication review is essential before starting therapy, and closer monitoring of blood pressure, blood sugar, and INR (for warfarin users) is warranted during titration.

Benefits Beyond the Scale

For many older adults, the most meaningful benefits of GLP-1 therapy aren't reflected in weight alone:

• Improved mobility and reduced joint pain
• Better blood pressure and lipid control (potentially reducing medication burden)
• Improved sleep quality (particularly for patients with sleep apnea)
• Enhanced energy and functional capacity
• Cardiovascular risk reduction